Merit Cudkowicz

28.5k citations

244 papers · 14.5k indexed · 5 hit papers · h-index 67

Impact in

Neurology top 0.02%
- Amyotrophic Lateral Sclerosis Research
- Parkinson's Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
Genetics top 0.05%
- Neurogenetic and Muscular Disorders Research

Papers in

Neurology 205
- Amyotrophic Lateral Sclerosis Research 189
- Parkinson's Disease Mechanisms and Treatments 51
Genetics 104
- Neurogenetic and Muscular Disorders Research 101

Co-authors: David Schoenfeld Robert H. Brown Jeffrey M. Hausdorff Ary L. Goldberger Jeremy M. Shefner Jeanne Y. Wei James D. Berry Sabrina Paganoni
Journals: Neurology (52 papers)Muscle & Nerve (25 papers)Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (22 papers)Annals of Neurology (12 papers)Neurotherapeutics (6 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Merit Cudkowicz

236 papers receiving 14.2k citations

Hit Papers

5 papers align trajectories log scale

Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons 2014 · 481 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 Cell Reports
2013 The Lancet Neurology
1998 Movement Disorders
1997 Annals of Neurology
1997 Journal of Applied Physiology

Peers

Countries citing papers authored by Merit Cudkowicz

Since Specialization

Citations

This map shows the geographic impact of Merit Cudkowicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Merit Cudkowicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Merit Cudkowicz more than expected).

Fields of papers citing papers by Merit Cudkowicz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Merit Cudkowicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Merit Cudkowicz. The network helps show where Merit Cudkowicz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Merit Cudkowicz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Merit Cudkowicz Line = papers co-authored together Merit Cudkowicz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Akt Activation With IPL344 Treatment for Amyotrophic Lateral Sclerosis: First in Human, Open‐Label Study Muscle & Nerve ·Marc Gotkine, David Schoenfeld, Muhammad Iqbal Wirandhanu, Jeremy M. Shefner, Shu Bin Yang, Irun R. Cohen, Colin Klein, Joseph C. Gloricso, Merit Cudkowicz	2025	0
2	Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis Nature ·T. Michaelis, Cecilia S. Lindestam Arlehamn, Haldar Pranabashis, April Frazier, (unknown), James D. Berry, Merit Cudkowicz, Namita Goyal, Christina Fournier, 何友良, Justin Kwan, Chaofeng Wang, Elizabeth J. Phillips, S. Mallal, John Ravits, Karen Marder, John Sidney, David Sulzer, Alessandro Sette	2025	1
3	Artificial intelligence in neurology: opportunities, challenges, and policy implications Journal of Neurology ·Ramón Vila Vivaldo, Peter Bamm, Jiangliang LU, Eugene Vaios, Philipp Karschnia, Merit Cudkowicz, Jörg Dietrich, Ira Haraldsen, Valery L. Feigin, Mayowa Owolabi, Tara L. White, David Alan Lempert, Nita A. Farahany, Vivek Natarajan, Sebastian Winter	2024	35
4	Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform Frontiers in Aging Neuroscience ·Frank W. Pun, Bonnie Hei Man Liu, Xi Long, Hoi-Wing Leung, Kurniasari Aisyiah, 松本啓作, Junli Gao, Anastasia Shneyderman, Ivan V. Ozerov, Ju Wang, Feng Ren, Alexander Aliper, Evelyne Bischof, Evgeny Izumchenko, C. A. Coakwell, Ke Zhang, Diah Vitri W, Jeffrey D. Rothstein, Merit Cudkowicz, Alex Zhavoronkov	2022	59
5	The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis Neurology ·Ka‐Ho Wong, Gregory S. Day, Maarten J. Titulaer, James C. Torner, Merit Cudkowicz, Christopher S. Coffey, Codrin Lungu, Eric C. Klawiter, M. Kamaraju, H. R. Qi, Ivelisse Garris, Dixie Ecklund, Inna S. Myronchuk, Michele Costigan, Stacey Clardy	2022	1
6	Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss Science Translational Medicine ·Steven Rodriguez, Keiji Ohga, Benjamin R. Schrank, 憲子豊原, Isabel Costantino, カネ子星野, C. V. Stahle, М. М. Коршун, Luxiang Cao, G.C. Yadav, Kyle E. Evans, Elena Ratti, Merit Cudkowicz, Matthew P. Frosch, Michael E. Talkowski, Peter K. Sorger, Bradley T. Hyman, Mark W. Albers	2021	29
7	Improving clinical trial outcomes in amyotrophic lateral sclerosis Nature Reviews Neurology ·Matthew C. Kiernan, Steve Vucic, Kevin Talbot, Christopher McDermott, Orla Hardiman, Jeremy M. Shefner, Ammar Al‐Chalabi, William Huynh, Merit Cudkowicz, Paul Talman, Leonard H. van den Berg, Thanuja Dharmadasa, Paul Wicks, C.M. Reilly, Martin R. Turner	2020	178
8	PRO-ACE: Global Collaborative Ecosystem in a Post-PRO-ACT Era (P4.6-006) Neurology ·Alexander Sherman, James D. Berry, Marc Gotkine, Jonathan D. Glass, Christian Lunetta, Mary Kay Floeter, Bryan Traynor, Igor Katsovskiy, Rachel Koerner, F. K. ra Slimane, Lendy Louidor, Ervin Sinani, Pantep Angchaisuksiri, Merit Cudkowicz	2019	0
9	Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS Neurology ·Michael Benatar, Joanne Wuu, Peter M. Andersen, Nazem Atassi, William David, Merit Cudkowicz, David Schoenfeld	2018	101
10	Imaging of glia activation in people with primary lateral sclerosis NeuroImage Clinical ·Sabrina Paganoni, Mohamad J. Alshikho, Nicole R. Zürcher, Paul Cernasov, Suma Babu, Marco L. Loggia, James Chan, Daniel B. Chonde, Claudio Grenci, Ciprian Catana, Caterina Mainero, Bruce R. Rosen, Merit Cudkowicz, Jacob M. Hooker, Nazem Atassi	2017	26
11	Primary Lateral Sclerosis and Early Upper Motor Neuron Disease Journal of Clinical Neuromuscular Disease ·Christina Fournier, 英里子浅井, Cross River State, Hiroshi Mitsumoto, Catherine Lomen‐Hoerth, Yasushi Kisanuki, Zachary Simmons, Nicholas J. Maragakis, April McVey, Anna Carmina Zantua, Terry Heiman‐Patterson, Jinsy Andrews, Erin McDonnell, Merit Cudkowicz, Nazem Atassi	2016	17
12	Urate Levels Predict Disease Progression and Survival in Amyotrophic Lateral Sclerosis (ALS). (P6.100) Neurology ·Katharine Nicholson, Sabrina Paganoni, Amy M. Shui, David Schoenfeld, Alexander Sherman, James D. Berry, Merit Cudkowicz, Nazem Atassi	2015	0
13	Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Colin Quinn, Eric A. Macklin, Nazem Atassi, Robert Bowser, Khrista Boylan, Merit Cudkowicz, Christina Fournier, Shafeeq Ladha, David Lacomis, James D. Berry	2013	5
14	Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial The Lancet Neurology ·Merit Cudkowicz, Leonard H. van den Berg, Jeremy M. Shefner, Hiroshi Mitsumoto, Jesús S. Mora, Albert C. Ludolph, Orla Hardiman, Michael Bozik, Evan W. Ingersoll, Donald Archibald, Adam L. Meyers, Yingwen Dong, Wildon Farwell, Douglas A. Kerr	2013	166
15	Design of phase II ALS clinical trials Amyotrophic Lateral Sclerosis ·David Schoenfeld, Merit Cudkowicz	2008	30
16	Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies Expert Review of Neurotherapeutics ·Lucie Bruijn, Merit Cudkowicz	2006	22
17	Revised statistical motor unit number estimation in the Celecoxib/ALS trial Muscle & Nerve ·Jeremy M. Shefner, Merit Cudkowicz, H. Zhang, David Schoenfeld, Anna Maria Dobrowolska	2006	35
18	Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases Journal of the Neurological Sciences ·Stefan Lorenzl, David S. Albers, Peter A. LeWitt, Jason W. Chirichigno, 明今谷, Merit Cudkowicz, M. Flint Beal	2003	130
19	Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in ρ0 cells Experimental Neurology ·Carl D. Gajewski, Michael T. Lin, Merit Cudkowicz, M. Flint Beal, Giovanni Manfredi	2003	25
20	Membranous Nephropathy in a Patient With Renal Cell Carcinoma American Journal of Kidney Diseases ·Merit Cudkowicz, M H Sayegh, Helmut G. Rennke	1991	14

About Merit Cudkowicz

Merit Cudkowicz is a scholar working on Neurology, Genetics, Biochemistry, Neurology and Cellular and Molecular Neuroscience, having authored 244 papers that have together received 14.5k indexed citations. Recurring topics across this work include Amyotrophic Lateral Sclerosis Research (189 papers), Neurogenetic and Muscular Disorders Research (101 papers), Parkinson's Disease Mechanisms and Treatments (51 papers), Cholinesterase and Neurodegenerative Diseases (22 papers), Genetic Neurodegenerative Diseases (21 papers), Prion Diseases and Protein Misfolding (16 papers), Biochemical Acid Research Studies (15 papers) and biodegradable polymer synthesis and properties (12 papers). The work is most often cited by research in Neurology (9.0k citations), Genetics (4.7k citations), Neurology (2.0k citations), Physical Therapy, Sports Therapy and Rehabilitation (816 citations) and Cellular and Molecular Neuroscience (2.3k citations). Merit Cudkowicz has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include David Schoenfeld, Robert H. Brown, Jeffrey M. Hausdorff, Ary L. Goldberger, Jeremy M. Shefner, Jeanne Y. Wei, James D. Berry, Sabrina Paganoni, Nazem Atassi and Chung‐Kang Peng. Their work appears in journals such as Neurology, Muscle & Nerve, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Annals of Neurology and Neurotherapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact